Combination of Hemodialysis With Hemoperfusion：A Clinical Study
NCT ID: NCT02461953
Last Updated: 2018-06-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
440 participants
INTERVENTIONAL
2015-06-30
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of pHA Hemoperfusion Plus Hemodialysis on Protein-Bound Uremic Toxins
NCT07016841
The Benefit of Hemodialysis Plus Hemoperfusion on Mortality
NCT03227770
Long-term, High Blood Flow Hemoadsorption Therapy in Patients Undergoing Maintenance Hemodialysis
NCT06574425
The Effect and Safety of Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients
NCT02747979
Impact of Regular Low-Frequency Hemoperfusion on Medium- to Long-Term Prognosis in Maintenance Dialysis Patients
NCT07348913
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
low flux hemodialysis
low flux hemodialysis alone, 3 times a week, 4 hours per session
low flux dialyzer
high flux hemodialysis
high flux hemodialysis alone, 3 times a week, 4 hours per session
high flux dialyzer
low flux hemodialysis + hemoperfusion
low flux hemodialysis 2times a week and the HD+HP once a week
hemoperfusion apparatus
low flux dialyzer
high flux hemodialysis + hemoperfusion
high flux hemodialysis 2times a week and the HD+HP once a week
hemoperfusion apparatus
high flux dialyzer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
hemoperfusion apparatus
low flux dialyzer
high flux dialyzer
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Maintenance hemodialysis duration\>3 months
3. Regular hemodialysis,3 times a week,4 hours per session
4. Vascular access unlimited
5. iPTH≥300pg/ml
6. Sign the written informed consent
Exclusion Criteria
2. PLT\<60×10\^9/L
3. Blood flow\<200ml/min
4. Serum albumin\<30g/L
5. Kt/V\<1.2
6. iPTH\>800pg/ml
7. Hemodiafiltration
8. Coagulation disorder, severe bleeding tendency, with active bleeding
9. Severe hypotension, severe cardiopulmonary insufficiency
10. Under other drug trial
11. Acute infection, severe heart, lung, liver, nervous diseases, malignant tumor
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese PLA General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiangmei Chen
Professor,Chief physician,Academician of Chinese Academy of Engineering,Chinese PLA General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.